New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 29, 2014
05:53 EDTQUREuniQure, Medison sign Glybera distribution agreement for Israel
uniQure N.V. and Medison Pharma announced an exclusive distribution agreement under which Medison will market Glybera, uniQure's gene therapy product for the treatment of lipoprotein lipase deficiency, or LPLD, in Israel and the Palestinian Authority. Medison will also be responsible for obtaining regulatory approval for Glybera in both territories. Financial terms of the agreement have not been disclosed. Glybera is approved in the EU as a treatment for LPLD, a potentially life-threatening, orphan metabolic disease that results in patients' inability to process fat in the blood after a meal.
News For QURE From The Last 14 Days
Check below for free stories on QURE the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 12, 2014
05:26 EDTQUREuniQure to host conference call
Conference call to discuss agreement to acquire InoCard will be held on August 12 at 8:30 am. Webcast Link
August 11, 2014
16:53 EDTQUREuniQure acquires InoCard in cash, stock
uniQure announced the acquisition of InoCard GmbH, an innovative, early-stage biotechnology company focused on the development of gene therapy approaches for cardiac disease. InoCard founders Patrick Most and Hugo Katus will join uniQure as managing director of uniQure in Germany and chairman of the scientific advisory board, for cardiovascular diseases, respectively. Under the terms of the agreement, InoCard shareholders will receive an upfront payment of 3M, 1.5M in cash and 1.5M in uniQure stock, and certain success-based milestones and royalties.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use